Previous 10 | Next 10 |
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT...
Purple Biotech ( NASDAQ: PPBT ) is trading ~10% higher after it agreed to acquire a private firm developing oncology therapies Immunorizon to expand its portfolio. Purple Biotech will acquire 100% of the shares of Immunorizon, VC-backed biopharmaceutical company, in...
Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic index for the compound REHOVOT, Israel, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Purple B...
Purple Biotech ( NASDAQ: PPBT ) stock rose ~6% on Tuesday after the company said it entered a research collaboration with Mor Research Applications. The agreement provides Purple first access to early-stage oncology product candidates owned by Mor, the company added. ...
REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immun...
Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/T...
Purple Biotech press release ( NASDAQ: PPBT ): Q3 GAAP EPS of -$0.27 misses by $0.07 . As of September 30, 2022, the Company had a total amount of $35.7 million in cash, cash equivalent and short and long term deposits. For further details see: Purple Biotech...
Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing f...
Therapies company Purple Biotech ( OTCPK:KITVF ) ( NASDAQ: PPBT ) appointed Lior Fhima CFO. Fhima was the CFO of Negev Ecology. Source: Press Release For further details see: Purple Biotech appoints CFO
Seasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnes...
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced further details on its ...
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...